OBJECTIVE: We previously identified CYR61 as a histone deacetylase 5 (HDAC-5)-repressed gene in systemic sclerosis (SSc; scleroderma) endothelial cells (ECs). When overexpressed, cysteine-rich angiogenic inducer 61 (CYR-61) promoted angiogenesis in SSc ECs. This study was undertaken to examine the role of CYR-61 in fibrosis and determine the mechanisms involved in CYR-61-mediated angiogenesis in SSc. METHODS: Dermal ECs and fibroblasts were isolated from biopsy specimens from healthy subjects and patients with SSc. CYR-61 level was determined by quantitative polymerase chain reaction, Western blotting, and enzyme-linked immunosorbent assay. CYR-61 was overexpressed using a CYR61 vector or knocked down using small interfering RNA, and functional and mechanistic studies were then conducted in fibroblasts and ECs. RESULTS: Lower CYR61 messenger RNA levels were observed in dermal fibroblasts and ECs from SSc patients than in those from healthy controls. In SSc fibroblasts, overexpression of CYR-61 led to significant reduction in the expression of profibrotic genes, including COL1A1 (P = 0.002) and ACTA2 (P = 0.04), and an increase in the expression of matrix-degrading genes, including MMP1 (P = 0.002) and MMP3 (P =0.004), and proangiogenic VEGF (P = 0.03). The antifibrotic effect of CYR-61 was further demonstrated by delay in wound healing, inhibition of gel contraction, inactivation of the transforming growth factor β pathway, and early superoxide production associated with senescence in SSc fibroblasts. In SSc ECs, overexpression of CYR-61 led to increased production of vascular endothelial cell growth factor. The proangiogenic effects of CYR-61 were mediated by signaling through αvβ3 receptors and downstream activation of AMP-activated protein kinase, AKT, and the endothelial cell nitric oxide synthase/nitric oxide pathway system. CONCLUSION: CYR-61, which is epigenetically regulated by HDAC-5, is a potent antifibrotic and proangiogenic mediator in SSc. Therapeutic intervention to promote CYR-61 activity or increase CYR-61 levels might be of benefit in SSc.
OBJECTIVE: We previously identified CYR61 as a histone deacetylase 5 (HDAC-5)-repressed gene in systemic sclerosis (SSc; scleroderma) endothelial cells (ECs). When overexpressed, cysteine-rich angiogenic inducer 61 (CYR-61) promoted angiogenesis in SSc ECs. This study was undertaken to examine the role of CYR-61 in fibrosis and determine the mechanisms involved in CYR-61-mediated angiogenesis in SSc. METHODS: Dermal ECs and fibroblasts were isolated from biopsy specimens from healthy subjects and patients with SSc. CYR-61 level was determined by quantitative polymerase chain reaction, Western blotting, and enzyme-linked immunosorbent assay. CYR-61 was overexpressed using a CYR61 vector or knocked down using small interfering RNA, and functional and mechanistic studies were then conducted in fibroblasts and ECs. RESULTS: Lower CYR61 messenger RNA levels were observed in dermal fibroblasts and ECs from SSc patients than in those from healthy controls. In SSc fibroblasts, overexpression of CYR-61 led to significant reduction in the expression of profibrotic genes, including COL1A1 (P = 0.002) and ACTA2 (P = 0.04), and an increase in the expression of matrix-degrading genes, including MMP1 (P = 0.002) and MMP3 (P =0.004), and proangiogenic VEGF (P = 0.03). The antifibrotic effect of CYR-61 was further demonstrated by delay in wound healing, inhibition of gel contraction, inactivation of the transforming growth factor β pathway, and early superoxide production associated with senescence in SSc fibroblasts. In SSc ECs, overexpression of CYR-61 led to increased production of vascular endothelial cell growth factor. The proangiogenic effects of CYR-61 were mediated by signaling through αvβ3 receptors and downstream activation of AMP-activated protein kinase, AKT, and the endothelial cell nitric oxide synthase/nitric oxide pathway system. CONCLUSION:CYR-61, which is epigenetically regulated by HDAC-5, is a potent antifibrotic and proangiogenic mediator in SSc. Therapeutic intervention to promote CYR-61 activity or increase CYR-61 levels might be of benefit in SSc.
Authors: Erawan Borkham-Kamphorst; Christian Schaffrath; Eddy Van de Leur; Ute Haas; Lidia Tihaa; Steffen K Meurer; Yulia A Nevzorova; Christian Liedtke; Ralf Weiskirchen Journal: Biochim Biophys Acta Date: 2014-01-31
Authors: Shervin Assassi; William R Swindell; Minghua Wu; Filemon D Tan; Dinesh Khanna; Daniel E Furst; Donald P Tashkin; Richard R Jahan-Tigh; Maureen D Mayes; Johann E Gudjonsson; Jeffrey T Chang Journal: Arthritis Rheumatol Date: 2015-11 Impact factor: 10.995
Authors: Abdelhakim Bouyahya; Naoufal El Hachlafi; Tarik Aanniz; Ilhame Bourais; Hamza Mechchate; Taoufiq Benali; Mohammad Ali Shariati; Pavel Burkov; José M Lorenzo; Polrat Wilairatana; Mohammad S Mubarak; Nasreddine El Omari Journal: Molecules Date: 2022-04-15 Impact factor: 4.927
Authors: Pamela J Palisoc; Leah Vaikutis; Mikel Gurrea-Rubio; Ellen N Model; Morgan M O'mara; Sarah Ory; Sirapa Vichaikul; Dinesh Khanna; Pei-Suen Tsou; Amr H Sawalha Journal: Front Immunol Date: 2022-02-24 Impact factor: 7.561
Authors: Sirapa Vichaikul; Mikel Gurrea-Rubio; M Asif Amin; Phillip L Campbell; Qi Wu; Megan N Mattichak; William D Brodie; Pamela J Palisoc; Mustafa Ali; Sei Muraoka; Jeffrey H Ruth; Ellen N Model; Dallas M Rohraff; Jonatan L Hervoso; Yang Mao-Draayer; David A Fox; Dinesh Khanna; Amr H Sawalha; Pei-Suen Tsou Journal: JCI Insight Date: 2022-05-09